Latest News & Features
Big Pharma
Sun Pharma’s Sezaby, used to treat infant seizures, infringes two patents says Nivagen | US firm accuses Indian rival of attempting to block patent from issuing. 25 January 2024
Big Pharma
Complaints say Slayback, Apotex and Baxter Healthcare infringed two patents through NDAs for leukaemia drug injection | Eagle patents issued in last two months expire in 2031. 23 January 2024
Americas
En banc petition concerning obviousness-type double-patenting rejected by the Court of Appeals | Decision on patent term adjustment has been closely followed by pharma companies, NYIPLA, and AIPLA. 23 January 2024
Asia
Five cases in which preliminary injunctions were granted are examined by Takanori Abe of Abe & Partners. 23 January 2024
Biotechnology
The office delivered its final written decision in favour of Daiichi Sankyo in a patent clash with Pfizer-owned unit | Concerns crucial tech in Daiichi’s cancer drug | Separate dispute concerning the same patent to continue in the US Court of Appeals. 18 January 2024
Biotechnology
Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal. 18 January 2024
Americas
Biotech company submitted a petition challenging an ‘incorrect’ ruling by the Court of Appeals for the Federal Circuit | Earlier decision invalidated several of Vanda’s patents in its sleep drug dispute against a pair of big pharma firms. 16 January 2024
Big Pharma
US biotech has launched multiple suits over alleged infringement of Eylea patents | Regeneron asks US court to block Amgen’s biosimilar before potential approval. 16 January 2024
Big Pharma
Case concerns a supplementary protection certificate granted to Gilead by Finland’s Patent Office for a HIV drug |CJEU judges contradict AG opinion on whether a Finnish regime is at odds with an EU directive. 11 January 2024
Biotechnology
SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions. 11 January 2024